CN112471504A - Special medical purpose formula food for epileptic and preparation method thereof - Google Patents
Special medical purpose formula food for epileptic and preparation method thereof Download PDFInfo
- Publication number
- CN112471504A CN112471504A CN202011470834.0A CN202011470834A CN112471504A CN 112471504 A CN112471504 A CN 112471504A CN 202011470834 A CN202011470834 A CN 202011470834A CN 112471504 A CN112471504 A CN 112471504A
- Authority
- CN
- China
- Prior art keywords
- oil
- epileptic
- special medical
- formula food
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001037 epileptic effect Effects 0.000 title claims abstract description 49
- 235000013305 food Nutrition 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 35
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 32
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 32
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 32
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 27
- 239000008158 vegetable oil Substances 0.000 claims abstract description 27
- 235000021323 fish oil Nutrition 0.000 claims abstract description 23
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 17
- 239000011707 mineral Substances 0.000 claims abstract description 17
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 13
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019742 Vitamins premix Nutrition 0.000 claims abstract description 12
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 9
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 9
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 9
- 235000021119 whey protein Nutrition 0.000 claims abstract description 9
- 150000004667 medium chain fatty acids Chemical class 0.000 claims abstract description 7
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 6
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims description 23
- 235000010755 mineral Nutrition 0.000 claims description 16
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 15
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- 238000001694 spray drying Methods 0.000 claims description 10
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229940001941 soy protein Drugs 0.000 claims description 6
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 claims description 5
- 235000019483 Peanut oil Nutrition 0.000 claims description 5
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 5
- 239000010495 camellia oil Substances 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 5
- 235000012343 cottonseed oil Nutrition 0.000 claims description 5
- 239000002385 cottonseed oil Substances 0.000 claims description 5
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- XBDUTCVQJHJTQZ-UHFFFAOYSA-L iron(2+) sulfate monohydrate Chemical compound O.[Fe+2].[O-]S([O-])(=O)=O XBDUTCVQJHJTQZ-UHFFFAOYSA-L 0.000 claims description 5
- 239000000944 linseed oil Substances 0.000 claims description 5
- 235000021388 linseed oil Nutrition 0.000 claims description 5
- 239000011564 manganese citrate Substances 0.000 claims description 5
- 235000014872 manganese citrate Nutrition 0.000 claims description 5
- 229940097206 manganese citrate Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 239000004006 olive oil Substances 0.000 claims description 5
- 235000008390 olive oil Nutrition 0.000 claims description 5
- 239000000312 peanut oil Substances 0.000 claims description 5
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 5
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 5
- 239000008159 sesame oil Substances 0.000 claims description 5
- 235000011803 sesame oil Nutrition 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 239000011781 sodium selenite Substances 0.000 claims description 5
- 235000015921 sodium selenite Nutrition 0.000 claims description 5
- 229960001471 sodium selenite Drugs 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- 229940118149 zinc sulfate monohydrate Drugs 0.000 claims description 5
- RNZCSKGULNFAMC-UHFFFAOYSA-L zinc;hydrogen sulfate;hydroxide Chemical compound O.[Zn+2].[O-]S([O-])(=O)=O RNZCSKGULNFAMC-UHFFFAOYSA-L 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 abstract description 16
- 230000036542 oxidative stress Effects 0.000 abstract description 11
- 206010010904 Convulsion Diseases 0.000 abstract description 6
- 208000028329 epileptic seizure Diseases 0.000 abstract description 5
- 235000019710 soybean protein Nutrition 0.000 abstract description 3
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 229930003270 Vitamin B Natural products 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 229930003448 Vitamin K Natural products 0.000 description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229940055726 pantothenic acid Drugs 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- 239000011713 pantothenic acid Substances 0.000 description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 4
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 4
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 4
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 235000019192 riboflavin Nutrition 0.000 description 4
- 239000002151 riboflavin Substances 0.000 description 4
- 235000019157 thiamine Nutrition 0.000 description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- 239000011721 thiamine Substances 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 235000019168 vitamin K Nutrition 0.000 description 4
- 239000011712 vitamin K Substances 0.000 description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- 229940046010 vitamin k Drugs 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 2
- 101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100096142 Panax ginseng SODCC gene Proteins 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 101150017120 sod gene Proteins 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a special medical application formula food for epileptics and a preparation method thereof, wherein each 100g of the special medical application formula food for epileptics contains: 10-20g of concentrated whey protein, 11-18g of soybean protein isolate, 10-20g of medium-chain fatty acid, 5-11g of vegetable oil powder, 18-30g of fish oil powder, 2-8g of fructo-oligosaccharide, 10-16g of maltodextrin, 0.01-0.5g of tryptophan, 3-8g of mineral premix and 0.05-0.15g of vitamin premix, and the components are uniformly mixed to prepare the finished product. The invention utilizes the metabolism of amino acid in vivo to relieve oxidative stress and prolong the epileptic seizure period of patients through the synergistic effect of various components.
Description
Technical Field
The invention relates to a nutritional preparation, in particular to a special medical application formula food for epileptics and a preparation method thereof, belonging to the technical field of biology.
Background
Epilepsy is a chronic nervous system disease, at present, the epileptic seizure of most patients can be controlled by medication, but some patients have poor response to the anti-epileptic medication, and the epileptic seizure is difficult to control, so that intractable epilepsy is formed. At present, more than 600 million epileptics in China are present, 65-70 million new epileptics are present each year, and about 25 percent of patients are intractable epileptics. Although the current diagnosis and treatment of epilepsy has advanced greatly, the number of intractable epilepsy patients is increasing.
In 2009, Fretias et al (Fretias R M D, Nasciento K G D, Ferreira P, et al, Neurochemical change on oxidative stress in a thioppocampus duringphase of pirocarpine-induced epilepsy [ J ]. Pharmacology Biochemistry and Behavior 2010, 94: 341-345.) demonstrated by rat experiments that oxidative stress plays an important role in the onset of epilepsy and that the duration of epilepsy was positively correlated with oxidative damage.
Tryptophan can relieve oxidative stress (NAYAK B N, BUTTAR H S. Evaluation of the antioxidant properties of tryptophans and its metabolites in the vitamin assay [ J ]. Journal of Complementary and integral Medicine, 2016, 13: 129-136.), the oxidative stress can enhance the catabolism of tryptophan, the amino group of tryptophan can be directly combined with an oxidizing agent, the oxidation reaction of other substances can be effectively prevented, and the antioxidant effect can be achieved. Melatonin, a metabolite of tryptophan, acts as a non-enzymatic antioxidant to scavenge free radicals in the body and also has antioxidant activity. At present, no nutritional functional food aiming at intractable epileptics exists in the market and literature reports.
Disclosure of Invention
The invention provides a special medical application formula food for epileptics and a preparation method thereof, aiming at prolonging the epileptic seizure period of patients by utilizing the influence of the metabolism of amino acid in vivo on oxidative stress.
The invention provides a special medical application formula food for epileptics, which is powder and is prepared by the following steps.
Formula food compound with special medical application
The formula food for the special medical application of the epileptic contains per 100 g:
10-20g of concentrated whey protein,
11-18g of the isolated soy protein,
10-20g of medium-chain fatty acid,
5-11g of vegetable oil powder,
18-30g of fish oil powder,
2-8g of fructo-oligosaccharide,
10-16g of maltodextrin, namely 10-16g,
0.01-0.5g of tryptophan,
3-8g of mineral premix, and the like,
0.05-0.15g of vitamin premix.
The vegetable oil powder is prepared from vegetable oil and edible carrier at a weight ratio of (40-50) to (40-50) by mixing vegetable oil and edible carrier, and spray drying to obtain powder.
The vegetable oil can be one or more of peanut oil, soybean oil, linseed oil, cottonseed oil, castor oil, rapeseed oil, sesame oil, olive oil, tea oil and the like.
The fish oil powder is prepared from fish oil and edible carrier at a weight ratio of (40-50) to (40-50), by mixing the fish oil and the edible carrier, and spray drying to obtain powder.
The edible carrier is maltodextrin.
Each gram of the mineral premix comprises 30-80 mg of calcium carbonate, 15-20 mg of magnesium chloride, 50-100 mg of edible salt, 80-150 mg of potassium chloride, 20-60 mg of monopotassium phosphate, 0.5-1.0 mg of ferrous sulfate monohydrate, 0.2-0.6 mg of zinc sulfate monohydrate, 0.001-0.01 mg of sodium selenite, 0.03-0.06 mg of anhydrous copper sulfate, 0.01-0.05 mg of manganese citrate, 0.005-0.01 mg of potassium iodide and the balance of mineral premix carrier.
The mineral premix carrier is maltodextrin.
Each gram of the vitamin premix comprises 2-5 mg of vitamin A, 0.03-0.06 mg of vitamin D, 500 mg of ascorbic acid 250-one, 30-60 mg of vitamin E, 10.1-0.5 mg of vitamin K, 3-6 mg of thiamine, 2-6 mg of riboflavin, 8-15 mg of nicotinamide, 15-20 mg of pantothenic acid, 3-6 mg of pyridoxine hydrochloride, 0.5-2.5 mg of folic acid, 0. 120.003-0.020 mg of vitamin B, 0.05-0.25 mg of biotin and the balance of vitamin premix carrier.
The vitamin premix carrier is maltodextrin.
② mixing the formula food with special medical application
Crushing the weighed nutrients, sieving with a 100-mesh sieve, and mixing and uniformly mixing by using a mixer.
The special medical formula food for the epileptics provided by the invention has the advantages of prolonging the seizure time of the epileptics, reducing the oxidative stress in the body of the epileptics and relieving the epileptics.
The formula food for the special medical application of the epileptic provided by the invention contains proteins such as soybean protein isolate and concentrated whey protein, has rich nitrogen source, better supplements the required protein, is rich in unsaturated fatty acids such as medium-chain fatty acid and DHA, and has important inhibiting effect on oxidative stress of the epileptic.
The formula food for the special medical application of the epileptic provided by the invention is particularly added with tryptophan, which is beneficial to relieving the oxidative stress of the epileptic and improving the immunity of the epileptic.
The special medical formula food for the epileptic provided by the invention adopts maltodextrin and other low GI carbohydrates, and is beneficial to controlling the blood sugar of the epileptic.
The formula food for the special medical application of the epileptic provided by the invention is a compound food, combines proteins such as soybean protein isolate, concentrated whey protein and the like, supplements required proteins, combines tryptophan to relieve the oxidative stress of the epileptic, combines low-GI carbohydrate such as maltodextrin to control the blood sugar of the patient, relieves the oxidative stress of the epileptic through the synergistic effect of various components, improves the immunity of the patient, and relieves the attack of the epileptic. The special medical purpose formula food for the epileptic can be used as a nutritional food for providing nutritional support for intractable epileptic, and can also be used as nutritional support for common epileptic.
Example 1:
formula food compound with special medical application
The formula food for the special medical application of the epileptic contains per 100 g:
14.34 g of concentrated whey protein is added,
14.43 g of the isolated soy protein,
15.15 g of medium-chain fatty acid,
8.31 g of vegetable oil powder,
23.46 g of fish oil powder,
5.06 g of fructo-oligosaccharide,
13.09 g of the maltodextrin, namely 13.09 g,
0.19 g of tryptophan (tryptophan) is added,
5.87 g of mineral premix, namely,
0.10 g of vitamin premix;
② mixing the formula food with special medical application
Crushing the weighed nutrients, sieving with a 100-mesh sieve, and mixing uniformly by using a mixer;
the vegetable oil powder consists of vegetable oil and maltodextrin in a weight ratio of 1:1, and is prepared by mixing the vegetable oil and the maltodextrin, and performing spray drying to prepare powder;
the vegetable oil can be one or more of peanut oil, soybean oil, linseed oil, cottonseed oil, castor oil, rapeseed oil, sesame oil, olive oil, tea oil and the like;
the fish oil powder consists of fish oil and maltodextrin in a weight ratio of 1:1, and is prepared by mixing the fish oil and the maltodextrin, and performing spray drying on the mixture to prepare powder;
each gram of the mineral premix comprises 56 mg of calcium carbonate, 18.3 mg of magnesium chloride, 83 mg of edible salt, 111 mg of potassium chloride, 40 mg of monopotassium phosphate, 0.83 mg of ferrous sulfate monohydrate, 0.4 mg of zinc sulfate monohydrate, 0.003 mg of sodium selenite, 0.044 mg of anhydrous copper sulfate, 0.025 mg of manganese citrate, 0.007 mg of potassium iodide and the balance of maltodextrin;
each gram of the vitamin premix comprises 3.6 mg of vitamin A, 0.048 mg of vitamin D, 336 mg of ascorbic acid, 48 mg of vitamin E, 10.264 mg of vitamin K, 4.2 mg of thiamine, 4.2 mg of riboflavin, 12 mg of nicotinamide, 17.4 mg of pantothenic acid, 4.2 mg of pyridoxine hydrochloride, 1.332 mg of folic acid, 120.0078 mg of vitamin B, 0.132 mg of biotin and the balance of maltodextrin.
Example 2:
formula food compound with special medical application
The formula food for the special medical application of the epileptic contains per 100 g:
10 g of concentrated whey protein is added into the concentrated whey protein,
14 g of the isolated soy protein (soy protein),
20g of medium-chain fatty acid,
6g of vegetable oil powder is prepared by mixing vegetable oil powder,
21.4 g of fish oil powder,
6g of fructo-oligosaccharide,
14.45 g of maltodextrin, namely 14.45 g,
0.1 g of tryptophan is added in the feed,
8g of mineral premix, namely 8g of mineral premix,
0.05 g of vitamin premix;
② mixing the formula food with special medical application
Crushing the weighed nutrients, sieving with a 100-mesh sieve, and mixing uniformly by using a mixer;
the vegetable oil powder consists of vegetable oil and maltodextrin in a weight ratio of 1:1, and is prepared by mixing the vegetable oil and the maltodextrin, and performing spray drying to prepare powder;
the vegetable oil can be one or more of peanut oil, soybean oil, linseed oil, cottonseed oil, castor oil, rapeseed oil, sesame oil, olive oil, tea oil and the like;
the fish oil powder consists of fish oil and maltodextrin in a weight ratio of 1:1, and is prepared by mixing the fish oil and the maltodextrin, and performing spray drying on the mixture to prepare powder;
each gram of the mineral premix comprises 56 mg of calcium carbonate, 18.3 mg of magnesium chloride, 83 mg of edible salt, 111 mg of potassium chloride, 40 mg of monopotassium phosphate, 0.83 mg of ferrous sulfate monohydrate, 0.4 mg of zinc sulfate monohydrate, 0.003 mg of sodium selenite, 0.044 mg of anhydrous copper sulfate, 0.025 mg of manganese citrate, 0.007 mg of potassium iodide and the balance of maltodextrin;
each gram of the vitamin premix comprises 3.6 mg of vitamin A, 0.048 mg of vitamin D, 336 mg of ascorbic acid, 48 mg of vitamin E, 10.264 mg of vitamin K, 4.2 mg of thiamine, 4.2 mg of riboflavin, 12 mg of nicotinamide, 17.4 mg of pantothenic acid, 4.2 mg of pyridoxine hydrochloride, 1.332 mg of folic acid, 120.0078 mg of vitamin B, 0.132 mg of biotin and the balance of maltodextrin.
Example 3:
formula food compound with special medical application
The formula food for the special medical application of the epileptic contains per 100 g:
20g of concentrated whey protein is added into the milk,
10 g of the isolated soy protein is extracted from the soybean,
10 g of medium-chain fatty acid,
10 g of the vegetable oil powder is added,
28 g of fish oil powder is prepared by grinding the fish oil,
2.6 g of fructo-oligosaccharide,
16g of maltodextrin, namely 16g of maltodextrin,
0.25 g of tryptophan was added thereto,
3 g of mineral premix, namely 3 g of mineral premix,
0.15g of vitamin premix;
② mixing the formula food with special medical application
Crushing the weighed nutrients, sieving with a 100-mesh sieve, and mixing uniformly by using a mixer;
the vegetable oil powder consists of vegetable oil and maltodextrin in a weight ratio of 1:1, and is prepared by mixing the vegetable oil and the maltodextrin, and performing spray drying to prepare powder;
the vegetable oil can be one or more of peanut oil, soybean oil, linseed oil, cottonseed oil, castor oil, rapeseed oil, sesame oil, olive oil, tea oil and the like;
the fish oil powder consists of fish oil and maltodextrin in a weight ratio of 1:1, and is prepared by mixing the fish oil and the maltodextrin, and performing spray drying on the mixture to prepare powder;
each gram of the mineral premix comprises 56 mg of calcium carbonate, 18.3 mg of magnesium chloride, 83 mg of edible salt, 111 mg of potassium chloride, 40 mg of monopotassium phosphate, 0.83 mg of ferrous sulfate monohydrate, 0.4 mg of zinc sulfate monohydrate, 0.003 mg of sodium selenite, 0.044 mg of anhydrous copper sulfate, 0.025 mg of manganese citrate, 0.007 mg of potassium iodide and the balance of maltodextrin;
each gram of the vitamin premix comprises 3.6 mg of vitamin A, 0.048 mg of vitamin D, 336 mg of ascorbic acid, 48 mg of vitamin E, 10.264 mg of vitamin K, 4.2 mg of thiamine, 4.2 mg of riboflavin, 12 mg of nicotinamide, 17.4 mg of pantothenic acid, 4.2 mg of pyridoxine hydrochloride, 1.332 mg of folic acid, 120.0078 mg of vitamin B, 0.132 mg of biotin and the balance of maltodextrin.
The invention provides the influence of the formula food for the special medical application of the epileptic patient on the epileptic attack of the mice:
constructing an epilepsia mouse model, taking the test of the example 1-3, only irrigating the stomach, setting a negative control group at the same time, irrigating the stomach with physiological saline of the negative control group, and normally feeding. Kunming mice, male, weight 18-22 g, each group of 10. Mice were gavaged daily for 4 weeks at a dose of 0.05 g/10 g. Weighing 1 time every day, observing the disease condition, taking blood from eyeball after last gastric lavage for 1 h, and detecting malondialdehyde content and enzyme activities of superoxide dismutase, glutathione peroxidase and SOD with malondialdehyde detection kit (Nanjing institute of bioengineering), superoxide dismutase detection kit (Nanjing institute of bioengineering), glutathione peroxidase detection kit (Nanjing institute of bioengineering), and SOD commercial detection kit (Biyuntian). The results of the influence of the formula food for special medical application of epileptics on the body weight of a mouse are shown in table 1, the results of the influence on the attack of epilepsy are shown in table 2, and the influences on the malonaldehyde content and the enzyme activity are shown in table 3.
TABLE 1 Effect of formula foods for specific medical uses on body weight of mice in epileptic patients
As can be seen from Table 1, there was no significant difference in the weight gain (P > 0.05) in the mice of examples 1-3, compared to the negative control group. Therefore, the preparation has no obvious influence on the weight increase of mice, and can maintain the normal physiological function of the mice.
TABLE 2 influence of formula food for special medical use of epileptic on onset of epilepsy in mice
As can be seen from Table 2, the formula food for the special medical use of the epileptic provided by the invention can obviously prolong the epileptic seizure period of mice and is beneficial to relieving epilepsy.
TABLE 3 influence of formula food for special medical use on blood index of mouse for epileptic
As can be seen from Table 3, the formula food for the special medical application of the epileptic provided by the invention can improve the enzyme activities of superoxide dismutase, glutathione peroxidase and SOD and reduce the content of malondialdehyde relative to a negative control group, and can relieve the epilepsy of mice.
Claims (8)
1. Formula food compound with special medical application
The formula food for the special medical application of the epileptic contains per 100 g:
10-20g of concentrated whey protein,
11-18g of the isolated soy protein,
10-20g of medium-chain fatty acid,
5-11g of vegetable oil powder,
18-30g of fish oil powder,
2-8g of fructo-oligosaccharide,
10-16g of maltodextrin, namely 10-16g,
0.01-0.5g of tryptophan,
3-8g of mineral premix, and the like,
0.05-0.15g of vitamin premix;
② mixing the formula food with special medical application
Crushing the weighed nutrients, sieving with a 100-mesh sieve, and mixing and uniformly mixing by using a mixer.
2. The food formulation for specific medical use of epileptic as claimed in claim 1, wherein said vegetable oil powder is composed of vegetable oil and edible carrier at a weight ratio of (40-50) to (40-50), and is obtained by mixing vegetable oil and edible carrier, spray drying to obtain powder.
3. The special medical formula food for epileptic according to claim 2, wherein said vegetable oil may be one or more of peanut oil, soybean oil, linseed oil, cottonseed oil, castor oil, rapeseed oil, sesame oil, olive oil, tea oil, etc.
4. The special medical formula food for epileptic according to claim 1, wherein the fish oil powder is composed of fish oil and edible carrier at a weight ratio of (40-50) to (40-50), and the fish oil powder is obtained by mixing the fish oil and the edible carrier, and spray-drying the mixture to obtain powder.
5. The epileptic specific medical use formula of claims 2-3, wherein the edible carrier is maltodextrin.
6. The formula food for special medical application of epileptic according to claim 1, wherein each 1g of the mineral premix comprises 30-80 mg of calcium carbonate, 15-20 mg of magnesium chloride, 50-100 mg of edible salt, 80-150 mg of potassium chloride, 20-60 mg of monopotassium phosphate, 0.5-1.0 mg of ferrous sulfate monohydrate, 0.2-0.6 mg of zinc sulfate monohydrate, 0.001-0.01 mg of sodium selenite, 0.03-0.06 mg of anhydrous copper sulfate, 0.01-0.05 mg of manganese citrate, 0.005-0.01 mg of potassium iodide and the balance of mineral premix carrier.
7. The special medical application formula food for the epileptic according to claim 1, wherein each 1g of the mineral premix comprises 50-60 mg of calcium carbonate, 18-19 mg of magnesium chloride, 80-90 mg of edible salt, 120 mg of potassium chloride 100-.
8. The epileptic specific medical use formula according to claims 6-7, wherein the premix carrier is maltodextrin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011470834.0A CN112471504A (en) | 2020-12-15 | 2020-12-15 | Special medical purpose formula food for epileptic and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011470834.0A CN112471504A (en) | 2020-12-15 | 2020-12-15 | Special medical purpose formula food for epileptic and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112471504A true CN112471504A (en) | 2021-03-12 |
Family
ID=74917038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011470834.0A Withdrawn CN112471504A (en) | 2020-12-15 | 2020-12-15 | Special medical purpose formula food for epileptic and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112471504A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114601172A (en) * | 2022-03-10 | 2022-06-10 | 山东若尧特医食品有限公司 | Formula food of glutamine composition with special medical application and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104082739A (en) * | 2014-06-24 | 2014-10-08 | 广州纽健生物科技有限公司 | Comprehensive nutritional and semi-digested formulated food for special medical use, and preparation method thereof |
CN108077911A (en) * | 2017-12-13 | 2018-05-29 | 上海奥医生物医药科技有限公司 | A kind of epileptic's tailored version clinical nutrition formula and preparation method thereof |
-
2020
- 2020-12-15 CN CN202011470834.0A patent/CN112471504A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104082739A (en) * | 2014-06-24 | 2014-10-08 | 广州纽健生物科技有限公司 | Comprehensive nutritional and semi-digested formulated food for special medical use, and preparation method thereof |
CN108077911A (en) * | 2017-12-13 | 2018-05-29 | 上海奥医生物医药科技有限公司 | A kind of epileptic's tailored version clinical nutrition formula and preparation method thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114601172A (en) * | 2022-03-10 | 2022-06-10 | 山东若尧特医食品有限公司 | Formula food of glutamine composition with special medical application and preparation method thereof |
CN114601172B (en) * | 2022-03-10 | 2024-03-19 | 山东若尧特医食品有限公司 | Formula food with special medical application of glutamine composition and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7790209B2 (en) | Total enteral nutritious composition | |
KR101344053B1 (en) | Compositions for ameliorating a reduced higher brain function resulting from organic brain lesions | |
US20200129463A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
US8388949B2 (en) | Compositions comprising pantothenic acid and their use for stimulating appetite | |
CN113397164A (en) | Special medical full-nutrition formula food for improving immunity and preparation method thereof | |
KR20100094485A (en) | Anti-fatigue agent comprising amino acid composition | |
WO2011096413A1 (en) | Agent for improving motility function | |
CN106376917A (en) | Health food or drink formula for regulating emotions from multiple aspects | |
CA2302641C (en) | Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation | |
CN113632848A (en) | Children milk powder beneficial to bone growth and preparation method thereof | |
CN112471504A (en) | Special medical purpose formula food for epileptic and preparation method thereof | |
KR101245364B1 (en) | Composition functioning to prevent or mitigate symptom or disease attributable to blood vessel aging | |
EP4082612A1 (en) | Composition containing sesamin and pqq | |
EP3135281B1 (en) | Composition for preventing or improving peripheral neuropathy | |
AU2004241884A2 (en) | A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein | |
JP2011157328A (en) | Mitochondria function-improving agent | |
CN109953347A (en) | A kind of collagen protein powder improving person in middle and old age's memory | |
JP2005082495A (en) | Cerebral cell-protecting composition | |
CN111869789A (en) | Special compound feed for improving survival rate of penaeus monodon in liver-turning period and preparation method and application thereof | |
CN113575969A (en) | Medical formula food containing tryptophan and used for relieving epilepsy and preparation method thereof | |
CN1364418A (en) | Diary product good for brain and reproduced food | |
RU2335927C2 (en) | Nutrient compositions enriched with leucine | |
JP2000302677A (en) | Medicine and food/feed composition having improving action on carnitine self production ability | |
JPH10273442A (en) | Bone metabolic improvement drug and nutritive composition | |
US20230232865A1 (en) | Feed supplements for feed for broiler chickens (variants), a method for producing a feed supplement for broiler chickens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210312 |